絞り込み

16525

広告

珍しい中型ティラノサウルス類の骨?…北海道 (読売新聞)

北海道大学は20日、北海道芦別市の白亜紀後期(約1億年~約6600万年前)の地層から見つかった恐竜の化石が、ティラノサウルス類の尾の骨である可能性が高いことが分...

  1. なぜ博士キャラは「〜じゃ」と話すの?リア...
  2. 【書評】中国のSF作家はどれだけ未来を見...
  3. エタノールから酢酸 合成方法を開発 (毎...
  4. DNAで恋が芽生える!新時代の婚活サービ...

ニュース一覧

Protease activated receptor 2 in diabetic nephropathy: a double edged sword.

著者 Waasdorp M , Duitman J , Florquin S , Spek AC
Am J Transl Res.2017 ; 9(10):4512-4520.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (46view , 0users)

Full Text Sources

Diabetic nephropathy is a major microvascular complication of diabetes mellitus, and the leading cause of end stage renal disease worldwide. The pathogenesis of diabetic nephropathy is complex, making the development of novel treatments that stop or reverse the progression of microalbuminuria into end stage renal disease a challenge. Protease activated receptor (PAR)-2 has recently been shown to aggravate disease progression in diabetic nephropathy based upon which it was suggested that PAR-2 would be a potential target for the treatment of diabetic nephropathy. To fully appreciate the translational potential of PAR-2 in diabetic nephropathy, we evaluated the effect of PAR-2 deficiency on the development of diabetic nephropathy in a streptozotocin-induced diabetes model characteristic of type 1 diabetes. Although diabetic PAR-2 deficient mice showed reduced albuminuria compared to diabetic wild type mice, an increase in mesangial expansion was evident in the PAR-2 deficient mice. No differences were observed in blood glucose levels, podocyte numbers or in glomerular vascular density. These results show that PAR-2 plays a dual role in the development of streptozotocin-induced diabetic nephropathy and may thus not be the eagerly awaited novel target to combat diabetic nephropathy. Targeting PAR-2 should consequently only be pursued with great care in a clinical setting.
PMID: 29118913 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード